Discovery + Development

Unlocking the potential of membrane proteins.

Abilita Therapeutics is a discovery and development company drugging the most challenging targets in medicine — multi-span membrane proteins long considered intractable — through directed evolution and AI-guided design.

See the science Explore the pipeline

Scroll

A discovery + development company

The most validated drug targets in medicine remain largely untapped.

Multi-span membrane proteins represent 60% of approved drug targets — yet only 15% of the more than 2,000 in the human proteome have ever been successfully drugged. Abilita's EMP™ platform turns the rest into tractable substrates for small-molecule, antibody, and ADC discovery.

16
MMP targets stabilised
5
Internal discovery programs
2
Cryo-EM structures determined
60%
of approved drugs target MMPs

EMP™ technology

Stabilising intractable targets through directed evolution.

At the core of Abilita is EMP™ — Enabled Membrane Protein technology — a directed-evolution approach that stabilises intractable receptors in defined active or inactive states. The result is a protein you can actually screen against, structure, and design drugs for.

How EMP works

Target classes + modalities

A protein you can actually screen, structure, and design drugs for.

AI/ML is embedded across the EMP™ discovery engine. Proprietary datasets generated by the platform feed task-specific models — including our internal StabLyzeGraph tool, co-developed with the Cosconati Lab — that guide design, ranking, and experimental planning. Lab in the loop, human in the loop.

Target classes

GPCRs
+ ion channels, transporters

Modalities

mAb · SM · ADC

EMP variants

Active &
inactive states

Pipeline

Six programs. First-in-class targets.

Six programs spanning oncology and metabolic disease. Internal small molecules and antibodies on first-in-class targets; partnered campaigns with global pharma. Every program is built on an EMP-stabilised receptor.

See the full pipeline

Target

Indication

Modality

EMP Generation

Discovery

Lead Optimization

IND-Enabling

Next Inflection

GPR75
Obesity
Small molecule
In vitro Lead — 2H 2026
GPR87
NSCLC, Head & Neck
mAb (ADCC or ADC)
In vivo POC — 1H 2027
GPR81
PDAC, TNBC
mAb
In vivo POC — 1H 2027
Multiple
Multiple
mAb / ADC
In vivo POC
CCR8
CRC, SCLC, others
mAb
Partnering activities ongoing
Undisclosed w/ Orion
Undisclosed
mAb
Partnered at discovery stage

Internal program Partnered program

Drugging targets previously considered undruggable.

Partnering, investment, and research inquiries welcome.

info@abilitatx.com